Pages that link to "Item:Q5701106"
From MaRDI portal
The following pages link to Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials (Q5701106):
Displaying 16 items.
- A conversation with Nancy Flournoy (Q254418) (← links)
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293) (← links)
- Operating characteristics of the standard phase I clinical trial design. (Q1285808) (← links)
- Methodology and application of adaptive and sequential approaches in contemporary clinical trials (Q1929694) (← links)
- Number of patients per cohort and sample size considerations using dose escalation with overdose control (Q1929695) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Cumulative cohort design for dose-finding (Q2455719) (← links)
- A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches (Q3019496) (← links)
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials (Q5438331) (← links)
- A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
- A straightforward meta-analysis approach for oncology phase I dose-finding studies (Q6628513) (← links)
- Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629388) (← links)
- Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial (Q6629425) (← links)
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design (Q6652600) (← links)
